Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab dose-ranging study in older adults with sarcopenia
2014-003482-25Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimagrumab in Sarcopenia (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline to week 25 in 6-minute walk test. Started Dec 2014; status: completed.
02
Drugs
bimagrumab
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on 2014-003482-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003482-25.